Skip to main content

Advertisement

SpringerLink
Log in

A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy

  • Published:
Biotherapy

Abstract

rTNF was administered to 28 patients with advanced metastatic cancers by continuous intra venous infusion for 5 consecutive days every 2 weeks. The dose levels were 30, 40, 70, 110, 180 and 290 µg/M2/day. Groups of 3 patients were started at each successive dose level and then on subsequent courses treated with the next dose level through 4 escalations as tolerated. Tumor types were: colon cancer 14; adenocarcinoma of unknown primary, 2; renal cancer, 2; leiomyosarcoma, 2; lung cancer, 1; prostate cancer, 1; thymona, 1; bladder cancer; 1; parotid, 1; Kaposi's sarcoma 2; ovarian 1. Toxicities included fever and chills (usually within the first 8 hours of infusion), fatigue, headache, decreased performance status, hypotension and CNS. All patients experienced leukopenia and thrombocytopenia within 24 hours or less after start of infusion with return of baseline by 72 hours after rTNF was stopped. The fall in these counts averaged 50% and was not dose related. No major changes in liver or renal function, coagulation or blood lipids were seen. Major dose limiting toxicities were fatigue, confusion, thrombocytopenia, seizures, hypotension and decreased performance status. NK cell activity measured against K562 target cells was augmented from about 30% target cell lysis to about 70% target cell lysis over the first 7 days of treatment. Two patients, both with metastatic colon cancer showed transient, objective tumor regression which did not qualify as a partial response. One patient with ovarian cancer had a stable partial response but progressed after 13 courses of treatment. Continuous infusion of TNF can be safely administered to patients with a maximum tolerated dose of only between 30 and 40 µg/M2/day. In addition, the MTD with continuous infusion seems to be highly variable and unpredictable from patient to patient. These data suggest that continuous infusion will not be an optimal way to administer TNF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci 1893; 105: 487–511.

    Google Scholar 

  2. Shear MJ, Turner FC, Perrault A, Shovelton T. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from serratia marcesens (Bacillus prodigiosus) culture filtrate. J. Natl Cancer Inst 1943; 4: 81–97.

    Google Scholar 

  3. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–70.

    Google Scholar 

  4. Mannel DN, Moore RN, Mergenhagen SE, Macrophages as a source of tumoricidal activity (tumor-necrotizing Factor). Infect Immun 1980; 30: 523–30.

    Google Scholar 

  5. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN. Human tumor necrosis factor production, purification and characterization. J Biol Chem 1985; 260: 2345–54.

    Google Scholar 

  6. Haranaka K, Satomi N, Sakuri A. Antitumor activity of murine Tumor Necrosis Factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984; 34: 263–67.

    Google Scholar 

  7. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF. Clinical pharmacology of recombinant tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987; 5: 1942–51.

    Google Scholar 

  8. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A Phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 1328–34.

    Google Scholar 

  9. Jakubowski AA, Casper ES, Gabrilove JL, Lester TJ, Sherwin S, Old LJ, Oettgen HF. Phase 1 trial of intramuscular administered tumor necrosis factor in adults with advanced cancer. Proc Am Soc Clin Oncol 1987; 6: 243.

    Google Scholar 

  10. 10. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei III E, Kufe DW. recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6: 344–50.

    Google Scholar 

  11. 11.Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ. Cell cycle-specific effects of tumor necrosis factor. Cancer Research 1984; 44: 83–90.

    Google Scholar 

  12. Kennett RH, McKearn TJ, Bechtol KB. Monoclonal antibodies hydribomas: A new dimension in biological analyses. New York and London: Plenum Press, 1980.

    Google Scholar 

  13. Charnetsky PS, Greisman RA, Salmon SE, Hersh EM, Scuderi P. Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor. Journal of Clinical Immunology (in press).

  14. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis protects mice from lethal effects of endotoxin. Science 1985; 229: 869–71.

    Google Scholar 

  15. Dinarello CA., Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, O'Connor JV. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986; 163: 1433–50

    Google Scholar 

  16. Taguchi T, Shiratori T, Kodama Met al. Clinical studies of recombinant human tumor necrosis factor. Proc. 14th Int Cancer Congress. 1986; 3: 2259 (abstr).

    Google Scholar 

  17. Kimura K, Taguchi T, Urushizaki I,et al. Clinical studies on recombinant human necrosis factor in patients with advanced malignancy. Proc. 14th Int. Cancer Congress 1986; 1: 389 (abstr).

    Google Scholar 

  18. Roodman GD, Lin L, Bird A, Montgomery W. Effects of tumor necrosis factor on hematopoietic cells. Blood 1986; 68: 178a (suppl 1: abstr).

    Google Scholar 

  19. Broxmeyer HE, Willaims DE, Lu Let al. The suppressive influences of human necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136: 4487–95.

    Google Scholar 

  20. Murphy M, Perussia B, Trinchieri G. Effects of recombinant tumor necrosis factor, lyphotoxin and interferon gamma on human bone marrow cells enriched for hematopoietic percursors. Blood 1986; 68: 173a (suppl 1: abstr).

    Google Scholar 

  21. Nawroth PP, Stem DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–45.

    Google Scholar 

  22. Morice RC, Blick MB, Ali MK. Gutterman JU. Pulmonary toxicity of recombinant tumor necrosis factor. Proc Am Soc Clin Oncol 1987; 6: 29.

    Google Scholar 

  23. Spriggs DR, Sherman ML, Frie III E, Kufe DW. Clinical studies with tumor necrosis factor. Tumour necrosis factor and related cytotoxins, Wiley, Chichester, Ciba Foundation Symposium 1987; 131: 206–27.

    Google Scholar 

  24. Savona S, Mittelman A, Singh B, Nadler P, Gaffney E, Skelos N, Coombe N, Ahmed T, Arlin Z. Neurotoxicity induced by continuous infusion of recombinant tumor necrosis factor in patients with advanced cancers. Proc Am Soc Clin Oncol. 1988; 7: 170.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology and Oncology, Arizona Cancer Center, University of Arizona, College of Medicine, Tucson, Arizona, USA

    Jonathan E. Schwartz, Philip Scuderi, Cyndy Wiggins & Evan M. Hersh

  2. Cetus Corporation, Emeryville, California, USA

    Alfred Rudolph

Authors
  1. Jonathan E. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philip Scuderi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cyndy Wiggins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alfred Rudolph
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Evan M. Hersh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwartz, J.E., Scuderi, P., Wiggins, C. et al. A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1, 207–214 (1989). https://doi.org/10.1007/BF02170889

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02170889

Keywords

Search

Navigation